In this video, Prof Xavier Bérard (University of Bordeaux, Bordeaux, FR) discusses the antimicrobial Intergard Synergy graft (Getinge) as an alternative solution for the in-situ reconstruction (ISR) of native or aortic graft infections (AGI) when biological methods are not possible.
He describes the protocols identifying the key cohorts who would benefit the most from antimicrobial grafts.
1. What prompted you to conduct this study?
2. What was the design, patient population and endpoints?
3. What are the key findings of this study?
4. Based on your findings, which cohort would benefit the most from antimicrobial grafts?
5. What conclusions can be made and what are the implications on practice?
6. What are the next steps?
Recorded remotely from Bordeaux, 2021.